Horizon Therapeutics Public Limited Company (HZNP) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - General industria. La empresa tiene su sede en Dublin, Ireland. El CEO actual es Timothy P. Walbert.
HZNP tiene fecha de IPO 2011-07-28, 2,190 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $26.6B.
Horizon Therapeutics Public Limited Company is a biotechnology company focused on discovering, developing, and commercializing medicines for rare, autoimmune, and severe inflammatory diseases. The company operates through two segments—Orphan and Inflammation—with a portfolio of 12 medicines spanning rare diseases, gout, ophthalmology, and inflammatory conditions. Its marketed products include TEPEZZA for thyroid eye disease, KRYSTEXXA for gout, RAVICTI and PROCYSBI for rare metabolic disorders, ACTIMMUNE for chronic granulomatous disease, and several anti-inflammatory and pain management therapies such as PENNSAID, DUEXIS, RAYOS, and VIMOVO. Founded in 2005 and headquartered in Dublin, Ireland, Horizon maintains research and commercial operations across multiple locations in the United States, Germany, and internationally through strategic collaborations with biotechnology partners.
